Hyperfine (NASDAQ:HYPR – Get Free Report) and Olympus (OTCMKTS:OCPNY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.
Profitability
This table compares Hyperfine and Olympus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -210.75% | -97.88% | -61.81% |
| Olympus | 13.80% | 24.30% | 9.30% |
Insider & Institutional Ownership
15.0% of Hyperfine shares are held by institutional investors. Comparatively, 0.0% of Olympus shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 0 | 2.40 |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
Hyperfine currently has a consensus price target of $2.03, suggesting a potential upside of 133.72%. Given Hyperfine’s higher probable upside, equities analysts plainly believe Hyperfine is more favorable than Olympus.
Valuation & Earnings
This table compares Hyperfine and Olympus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperfine | $16.54 million | 5.58 | -$35.57 million | ($0.38) | -2.29 |
| Olympus | $7.74 billion | 2.99 | $1.03 billion | $0.82 | 21.95 |
Olympus has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Hyperfine has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Olympus has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
Summary
Olympus beats Hyperfine on 8 of the 14 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
About Olympus
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
